TORONTO, March 21, 2023 /PRNewswire/ – Diamond Therapeutics Inc. (“Diamond”), a drug development company focused on low-dose psychedelic-derived therapies for use in the treatment of mental health, is pleased to announce the FDA’s authorization of the IND application submitted by collaborator Dr. Peter Hendricks. The FDA’s authorization allows Dr. Hendricks to proceed with a human clinical trial…


Previous articleRevive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
Next articleWesana Health Announces Sale of SANA-13 Assets to Lucy Scientific Discovery